ADBiotech Co

ADBiotech Co Receivables

The Accounts Receivable of ADBiotech Co (179530.KQ) as of Oct 20, 2026 is 2.94 B KRW. In the previous year, Accounts Receivable was 1.60 B KRW — a change of 83.13% (higher).

Receivables

2.94 BKRW

YoY

83.13%

Last updated:

Accounts Receivable of ADBiotech Co is 2024 2.94 B KRW. Accounts Receivable of ADBiotech Co was 2023 1.60 B KRW. It decreases by 83.13% higher compared to the previous year.

The ADBiotech Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
905.56 M KRW
Jan 1, 2018
852.74 M KRW
Jan 1, 2019
1.41 B KRW
Jan 1, 2020
1.73 B KRW
Jan 1, 2021
3.50 B KRW
Jan 1, 2022
1.92 B KRW
Jan 1, 2023
1.60 B KRW
Jan 1, 2024
2.94 B KRW
The ADBiotech Co Receivables history
YEARReceivablesYoY
2.94 BKRW+83.13%
1.60 BKRW-16.44%
1.92 BKRW-45.12%
3.50 BKRW+101.70%
1.73 BKRW+23.18%
1.41 BKRW+65.08%
852.74 MKRW-5.83%
905.56 MKRW+21.14%
747.53 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ADBiotech Co Stock analysis

What does ADBiotech Co do? ADbiotech Co., Ltd. generates revenue by manufacturing and selling chemical products across two distinct business segments. The Veterinary Medicine segment focuses on the production of antibiotics, anticoccidial agents, antimicrobial agents, nervous system agents, and synthetic antibacterial agents for use in pharmaceuticals and stockbreeding. This division serves customers in the animal health sector by providing essential medical compounds for livestock and other animals. The Supplementary Feed segment complements the core operations by manufacturing and selling functional supplementary feeds and other related products. This segment targets the stockbreeding and fisheries industries, offering nutritional solutions to enhance animal health and productivity. By combining these two segments, ADBiotech Co., Ltd. delivers a comprehensive range of chemical and feed-based solutions to its clients in Chuncheon, Gangwon-Do. ADBiotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ADBiotech Co stock

Accounts Receivable of ADBiotech Co is 2.94 B KRW in 2024.

Accounts Receivable of ADBiotech Co changed from 1.60 B KRW to 2.94 B KRW, representing a 83.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable ADBiotech Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's ADBiotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — ADBiotech Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — ADBiotech Co